Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structu... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of A... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent St... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinati... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Adv... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Comp... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared wi... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherap... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccination... Read More
Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients (... Read More